Inogen earnings release, May 7, 2026

Inogen Inc (INGN) · Form 8-K, Item 2.02 · Filed · SEC filing

Inogen Announces First Quarter 2026 Financial Results

Reported first quarter year-over-year revenue growth of 3.4%

Company reiterates full-year 2026 guidance

BEVERLY, Mass.,

May 7, 2026 --

Inogen, Inc.

(Nasdaq:

INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2026 and reiterated its full-year guidance.

“Our first quarter revenue exceeded our outlook with revenue growth of 3.4% as we continue to execute on our clinical and strategic priorities that we believe will position us for growth acceleration and improved profitability in the second half of the year and beyond” said Kevin Smith, Inogen’s Chief Executive Officer. “Our progress reflects the power of our strategy as we expand our addressable markets, differentiate our portfolio with clinical evidence, and broaden our portfolio through innovation as we generate long-term sustained growth, profitability and value creation for our stockholders.”

Highlights

• Exceeded guidance with first quarter revenue growth of 3.4% from the prior-year period and reiterated full-year 2026 revenue outlook.

• Authorized a $30.0 million share repurchase program to return capital to stockholders.

• Introduced Aurora continuous positive airway pressure, or CPAP, masks in the U.S., entering the obstructive sleep apnea, or OSA, market with FDA-cleared products designed for comfort, reliability, and wide compatibility.

• Received acceptance of the Aurora CPAP mask study – Patient Preference, Comfort, and Satisfaction with a Novel Full-Face CPAP Mask: A 90-Day In-Home Evaluation Among Experienced Users – to be presented at SLEEP 2026 in Baltimore, Maryland.

• Launched the Rove 6 portable oxygen concentrator in Brazil, strengthening Inogen's ongoing international market expansion.

• Initiated patient enrollment in IMPACTS-200, the first U.S. Simeox 200 reimbursement trial.

• Strengthened the executive leadership team with the appointment of Jason Richardson as Chief Financial Officer and Dominic Hulton as Chief Marketing Officer to help enable Inogen’s next phase of growth.

• Added additional medical technology experience to the Inogen Board of Directors with the appointment of Vafa Jamali, to take effect on June 5, 2026.

First Quarter 2026 Financial Results

Total revenue in the first quarter of 2026 was $85.1 million, an increase of 3.4% from the prior-year period, primarily driven by higher demand for portable oxygen concentrators, or POCs, in international markets and the favorable impact of foreign exchange rates, which more than offset lower U.S. sales and U.S. rentals.

Total gross margin was 44.5% in the first quarter of 2026 compared to 44.2% in the prior-year period. Adjusted gross margin improved by 30 basis points to 44.7% compared to 44.4% in the prior-year period due to cost improvements in the total cost of revenue.

GAAP net loss for the first quarter of 2026 was $8.3 million compared to a net loss of $6.2 million in the prior-year period. Adjusted net loss for the first quarter of 2026 was $4.0 million compared to adjusted net loss of $2.9 million in the prior-year period.

Adjusted EBITDA was negative $1.4 million in the first quarter of 2026, compared to positive $0.04 million in the prior-year period due to investments in research and development to position the Company for sustained, future growth.

Cash, cash equivalents, marketable securities, and restricted cash were $111.5 million as of March 31, 2026, with no debt outstanding. The Company repurchased 298,100 shares of its common stock for consideration of $1.9 million under the recently announced share repurchase program.

Reconciliations of adjusted gross margin, adjusted net loss, and adjusted EBITDA for the three months ended March 31, 2026 and 2025 are in the financial schedules that are a part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures.”

Second Quarter and Full Year 2026 Financial Outlook

For the second quarter of 2026, Inogen expects reported revenue in the range of $94 million to $97 million, reflecting approximately 3.5% growth at the midpoint of the range relative to the Company’s second quarter 2025 revenue.

For the full year 2026, Inogen continues to expect reported revenue in the range of $366 million to $373 million, reflecting approximately 6.0% growth at the midpoint of the range relative to the Company’s 2025 revenue.

The Company remains committed to driving positive adjusted EBITDA improvement in 2026.

Quarterly Conference Call Information

On May 7, 2026, the Company will host a conference call at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.

Individuals interested in listening to the conference call may do so by dialing:

U.S. domestic callers (877) 841-3961

Non-U.S. callers (201) 689-8589

Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the

News / Events page on the Inogen

Investor Relations website. This webcast will also be archived on the website for six months.

A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through May 14, 2026. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13759464.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Inogen... (truncated)ing. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.

For more information, please visit www.inogen.com.

Financial statements

Income Statement

Three months ended March 31, — (amounts in thousands, except share and per share amounts)

Three months ended March 31, – 2026Three months ended March 31, – 2025
RevenueSales revenue72,40468,470
RevenueRental revenue12,70513,810
RevenueTotal revenue85,10982,280
Cost of revenueCost of sales revenue40,17738,083
Cost of revenueCost of rental revenue, including depreciation of $2,628 and $3,034, respectively7,0697,825
Cost of revenueTotal cost of revenue47,24645,908
Cost of revenueGross profit37,86336,372
Operating expenseResearch and development5,0974,034
Operating expenseSales and marketing24,60323,757
Operating expenseGeneral and administrative17,49916,237
Operating expenseTotal operating expense47,19944,028
Operating expenseLoss from operations-9,336-7,656
Other incomeInterest income, net8801,029
Other incomeOther (expense) income, net-42356
Other incomeTotal other income, net8381,385
Other incomeLoss before benefit for income taxes-8,498-6,271
Other incomeBenefit for income taxes-174-97
Other incomeNet loss-8,324-6,174
Other comprehensive (loss) income, net of taxChange in foreign currency translation adjustment-8451,855
Other comprehensive (loss) income, net of taxChange in net unrealized losses on foreign currency hedging-37-732
Other comprehensive (loss) income, net of taxLess: reclassification adjustment for net gains (losses) included in net loss37-133
Other comprehensive (loss) income, net of taxTotal net change in unrealized losses on foreign currency hedging-865
Other comprehensive (loss) income, net of taxChange in net unrealized gains on marketable securities17
Other comprehensive (loss) income, net of taxTotal other comprehensive (loss) income, net of tax-828990
Other comprehensive (loss) income, net of taxComprehensive loss-9,152-5,184
Other comprehensive (loss) income, net of taxBasic net loss per share attributable to common stockholders (1)-0.3-0.25
Other comprehensive (loss) income, net of taxDiluted net loss per share attributable to common stockholders (1) (2)-0.3-0.25
Weighted average number of shares used in calculating net loss per share attributable to common stockholders:Basic shares of common stock27,322,43825,164,444
Weighted average number of shares used in calculating net loss per share attributable to common stockholders:Diluted shares of common stock27,322,43825,164,444

Income Statement

(in thousands, except units and patients)

Three months ended – March 31, – 2026Three months ended – March 31, – 2025Change 2026 vs. 2025 – $$Change 2026 vs. 2025 – %Constant – Currency – Change – %
U.S. sales34,73636,485-1,749-4.8%-4.8%
International sales37,66831,9855,68317.8%5.9%
U.S. rentals12,70513,810-1,105-8.0%-8.0%
Total revenue85,10982,2802,8293.4%-1.2%
Additional financial measuresUnits sold49,00043,000
Additional financial measuresNet rental patients as of period-end47,30050,400

Balance Sheet

March 31, 2026 — (amounts in thousands)

March 31, 2026December 31, 2025
Current assetsCash and cash equivalents93,112103,729
Current assetsMarketable securities17,05915,848
Current assetsRestricted cash1,2961,289
Current assetsAccounts receivable, net41,87438,863
Current assetsInventories24,99225,969
Current assetsPrepaid expenses and other current assets12,33212,601
Current assetsTotal current assets190,665198,299
Current assetsProperty and equipment, net33,68636,362
Current assetsGoodwill10,48310,698
Current assetsIntangible assets, net28,91030,763
Current assetsOperating lease right-of-use asset15,72816,501
Current assetsOther assets6,4546,002
Current assetsTotal assets285,926298,625
Current liabilitiesAccounts payable and accrued expenses32,69533,941
Current liabilitiesAccrued payroll10,19210,629
Current liabilitiesWarranty reserve - current9,97810,116
Current liabilitiesOperating lease liability - current3,4923,163
Current liabilitiesDeferred revenue - current5,0905,503
Current liabilitiesIncome tax payable183
Current liabilitiesTotal current liabilities61,44763,535
Long-term liabilitiesWarranty reserve - noncurrent18,38818,194
Long-term liabilitiesOperating lease liability - noncurrent13,44314,313
Long-term liabilitiesDeferred revenue - noncurrent3,1703,603
Long-term liabilitiesDeferred tax liability6,5726,749
Long-term liabilitiesTotal liabilities103,020106,394
Stockholders' equityCommon stock2727
Stockholders' equityAdditional paid-in capital363,372363,545
Stockholders' equityAccumulated deficit-183,908-175,584
Stockholders' equityAccumulated other comprehensive income3,4154,243
Stockholders' equityTotal stockholders' equity182,906192,231
Stockholders' equityTotal liabilities and stockholders' equity285,926298,625

Cash Flow

Three months ended March 31, — (amounts in thousands)

Three months ended March 31, – 2026Three months ended March 31, – 2025
Cash flows from operating activitiesNet loss-8,324-6,174
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization4,9045,189
Adjustments to reconcile net loss to net cash used in operating activities:Loss on rental units and other assets563925
Adjustments to reconcile net loss to net cash used in operating activities:Provision for sales revenue returns and doubtful accounts2,0511,714
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen’s future business plans, market opportunities, financial outlook, growth strategies, and anticipated operational results, are forward-looking statements. Words such as “aims,” “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks and uncertainties relating to Inogen’s 2026 second quarter and full year financial guidance; market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the period ended December 31, 2025, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.

Non-GAAP Financial Measures

Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three months ended March 31, 2026, and March 31, 2025. Management believes that these non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of Inogen’s core operating results. Management uses these non-GAAP measures to compare Inogen’s performance relative to forecasts and strategic plans, to benchmark Inogen’s performance externally against competitors, and for certain compensation decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Inogen's operating results as reported under U.S. GAAP. Inogen encourages investors to carefully consider its results under U.S. GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between U.S. GAAP and non-GAAP results are presented in the accompanying tables of this release.

Contact ir@inogen.net

Consolidated Statements of Comprehensive Loss

(unaudited)

(amounts in thousands, except share and per share amounts)

(1) Reconciliations of net loss attributable to common stockholders basic and diluted can be found in Inogen’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 to be filed with the Securities and Exchange Commission.

(2) Due to a net loss for the three months ended March 31, 2026 and March 31, 2025, diluted loss per share is the same as basic.

Consolidated Balance Sheets

(unaudited)

(amounts in thousands)

Condensed Consolidated Cash Flow

(unaudited)

(amounts in thousands)

Supplemental Financial Information

(unaudited)

(in thousands, except units and patients)

Reconciliation of U.S. GAAP to Non-GAAP Financial Measures

(unaudited)

(in thousands, except per share amounts)

(1) Stockholder engagement and proxy defense costs include third-party advisory, legal, and other professional fees.

(2) Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of 0% for 2026 and 2025.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Inogen earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.